109 related articles for article (PubMed ID: 25473890)
1. AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis.
Li CF; Chen LT; Lan J; Chou FF; Lin CY; Chen YY; Chen TJ; Li SH; Yu SC; Fang FM; Tai HC; Huang HY
Oncotarget; 2014 Nov; 5(22):11588-603. PubMed ID: 25473890
[TBL] [Abstract][Full Text] [Related]
2. AMACR amplification in myxofibrosarcomas: a mechanism of overexpression that promotes cell proliferation with therapeutic relevance.
Li CF; Fang FM; Lan J; Wang JW; Kung HJ; Chen LT; Chen TJ; Li SH; Wang YH; Tai HC; Yu SC; Huang HY
Clin Cancer Res; 2014 Dec; 20(23):6141-52. PubMed ID: 25384383
[TBL] [Abstract][Full Text] [Related]
3. Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics.
Li CF; Wang JM; Kang HY; Huang CK; Wang JW; Fang FM; Wang YH; Wu WR; Li SH; Yu SC; Lee JC; Lan J; Shiue YL; Wu LC; Huang HY
Clin Cancer Res; 2012 Mar; 18(6):1598-610. PubMed ID: 22322669
[TBL] [Abstract][Full Text] [Related]
4. Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.
Li CF; Fang FM; Chen YY; Liu TT; Chan TC; Yu SC; Chen LT; Huang HY
Clin Cancer Res; 2017 Aug; 23(16):4908-4918. PubMed ID: 28442505
[No Abstract] [Full Text] [Related]
5. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
Bauer S; Duensing A; Demetri GD; Fletcher JA
Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
[TBL] [Abstract][Full Text] [Related]
6. Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors.
Li CF; Huang WW; Wu JM; Yu SC; Hu TH; Uen YH; Tian YF; Lin CN; Lu D; Fang FM; Huang HY
Clin Cancer Res; 2008 Dec; 14(23):7822-31. PubMed ID: 19047110
[TBL] [Abstract][Full Text] [Related]
7. Transcriptomic reappraisal identifies MGLL overexpression as an unfavorable prognosticator in primary gastrointestinal stromal tumors.
Li CF; Chuang IC; Liu TT; Chen KC; Chen YY; Fang FM; Li SH; Chen TJ; Yu SC; Lan J; Huang HY
Oncotarget; 2016 Aug; 7(31):49986-49997. PubMed ID: 27366945
[TBL] [Abstract][Full Text] [Related]
8. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
[TBL] [Abstract][Full Text] [Related]
9. Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells.
Berglund E; Ubhayasekera SJ; Karlsson F; Akcakaya P; Aluthgedara W; Ahlen J; Fröbom R; Nilsson IL; Lui WO; Larsson C; Zedenius J; Bergquist J; Bränström R
Anticancer Drugs; 2014 Apr; 25(4):415-22. PubMed ID: 24361761
[TBL] [Abstract][Full Text] [Related]
10. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor.
Trent JC; Ramdas L; Dupart J; Hunt K; Macapinlac H; Taylor E; Hu L; Salvado A; Abbruzzese JL; Pollock R; Benjamin RS; Zhang W
Cancer; 2006 Oct; 107(8):1898-908. PubMed ID: 16986125
[TBL] [Abstract][Full Text] [Related]
11. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
[TBL] [Abstract][Full Text] [Related]
12. PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: Integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival.
Li CF; Liu TT; Chuang IC; Chen YY; Fang FM; Chan TC; Li WS; Huang HY
Oncotarget; 2017 Mar; 8(12):19997-20010. PubMed ID: 28212550
[TBL] [Abstract][Full Text] [Related]
13. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.
Lartigue L; Neuville A; Lagarde P; Brulard C; Rutkowski P; Dei Tos P; Wardelmann E; Debiec-Rychter M; Italiano A; Coindre JM; Chibon F
Eur J Cancer; 2015 Jan; 51(1):75-83. PubMed ID: 25466504
[TBL] [Abstract][Full Text] [Related]
14. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
Lee JH; Kim Y; Choi JW; Kim YS
J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
[TBL] [Abstract][Full Text] [Related]
15. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
[TBL] [Abstract][Full Text] [Related]
16. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
[TBL] [Abstract][Full Text] [Related]
17. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
Bauer S; Yu LK; Demetri GD; Fletcher JA
Cancer Res; 2006 Sep; 66(18):9153-61. PubMed ID: 16982758
[TBL] [Abstract][Full Text] [Related]
19. CEBPD amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognosis.
Wang YH; Wu WJ; Wang WJ; Huang HY; Li WM; Yeh BW; Wu TF; Shiue YL; Sheu JJ; Wang JM; Li CF
Oncotarget; 2015 Oct; 6(31):31069-84. PubMed ID: 26307680
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
Li J; Dang YZ; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
